158 related articles for article (PubMed ID: 25885126)
21. CDX-2 and HER-3 expression in canine gastric and colorectal adenocarcinomas.
Doster AR; Yhee JY; Kim JH; Im KS; Sur JH
J Comp Pathol; 2011 Jul; 145(1):12-9. PubMed ID: 21238975
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia-inducible factor-1alpha modulates the down-regulation of the homeodomain protein CDX2 in colorectal cancer.
Zheng J; Sun X; Wang W; Lu S
Oncol Rep; 2010 Jul; 24(1):97-104. PubMed ID: 20514449
[TBL] [Abstract][Full Text] [Related]
23. [Expression of the cdx2 gene in benign intestinal-type mucinous ovarian tumors].
Gaggero G; Sola S; Mora M; Fulcheri E
Pathologica; 2003 Aug; 95(4):185-91. PubMed ID: 14577202
[TBL] [Abstract][Full Text] [Related]
24. Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum.
Groisman GM; Bernheim J; Halpern M; Brazowsky E; Meir A
Arch Pathol Lab Med; 2005 Jul; 129(7):920-3. PubMed ID: 15974817
[TBL] [Abstract][Full Text] [Related]
25. CDX-2 expression in pulmonary fine-needle aspiration specimens: a useful adjunct for the diagnosis of metastatic colorectal adenocarcinoma.
Levine PH; Joutovsky A; Cangiarella J; Yee H; Simsir A
Diagn Cytopathol; 2006 Mar; 34(3):191-5. PubMed ID: 16470859
[TBL] [Abstract][Full Text] [Related]
26. Expression pattern of CK7, CK20, CDX-2, and villin in intestinal-type sinonasal adenocarcinoma.
Kennedy MT; Jordan RC; Berean KW; Perez-Ordoñez B
J Clin Pathol; 2004 Sep; 57(9):932-7. PubMed ID: 15333652
[TBL] [Abstract][Full Text] [Related]
27. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
[TBL] [Abstract][Full Text] [Related]
28. Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer.
Hong KD; Lee D; Lee Y; Lee SI; Moon HY
Am Surg; 2013 Apr; 79(4):353-60. PubMed ID: 23574843
[TBL] [Abstract][Full Text] [Related]
29. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2.
Panarelli NC; Yantiss RK; Yeh MM; Liu Y; Chen YT
Am J Clin Pathol; 2012 Aug; 138(2):211-22. PubMed ID: 22904132
[TBL] [Abstract][Full Text] [Related]
30. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
31. CDX-2 immunostaining in primary and secondary ovarian carcinomas.
Tornillo L; Moch H; Diener PA; Lugli A; Singer G
J Clin Pathol; 2004 Jun; 57(6):641-3. PubMed ID: 15166272
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical analysis of CDX2 expression in normal choroid plexus epithelium and choroid plexus tumors.
Beschorner R; Mittelbronn M; Mugler M; Meyermann R; Schittenhelm J
Histol Histopathol; 2009 Dec; 24(12):1507-14. PubMed ID: 19795349
[TBL] [Abstract][Full Text] [Related]
33. The Diagnostic Value of Cadherin 17 and CDX2 Expression as Immunohistochemical Markers in Colorectal Adenocarcinoma.
Abouelkhair MB; Mabrouk SH; Zaki SSA; Nada OH; Hakim SA
J Gastrointest Cancer; 2021 Sep; 52(3):960-969. PubMed ID: 32929682
[TBL] [Abstract][Full Text] [Related]
34. LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms.
Kermanshahi TR; Jayachandran P; Chang DT; Pai R
Appl Immunohistochem Mol Morphol; 2014; 22(10):728-34. PubMed ID: 25394300
[TBL] [Abstract][Full Text] [Related]
35. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma.
Saad RS; Silverman JF; Khalifa MA; Rowsell C
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):196-201. PubMed ID: 19098678
[TBL] [Abstract][Full Text] [Related]
36. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
Suh N; Yang XJ; Tretiakova MS; Humphrey PA; Wang HL
Mod Pathol; 2005 Sep; 18(9):1217-22. PubMed ID: 15803184
[TBL] [Abstract][Full Text] [Related]
37. Expression of phosphorylated Ser70 of Bcl-2 correlates with malignancy in human colorectal neoplasms.
Kondo E; Miyake T; Shibata M; Kimura T; Iwagaki H; Nakamura S; Tanaka T; Ohara N; Ichimura K; Oka T; Yanai H; Shibasaki F; Yoshino T
Clin Cancer Res; 2005 Oct; 11(20):7255-63. PubMed ID: 16243795
[TBL] [Abstract][Full Text] [Related]
38. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
39. Divergent expression of MUC5AC, MUC6, MUC2, CD10, and CDX-2 in dysplasia and intramucosal adenocarcinomas with intestinal and foveolar morphology: is this evidence of distinct gastric and intestinal pathways to carcinogenesis in Barrett Esophagus?
Khor TS; Alfaro EE; Ooi EM; Li Y; Srivastava A; Fujita H; Park Y; Kumarasinghe MP; Lauwers GY
Am J Surg Pathol; 2012 Mar; 36(3):331-42. PubMed ID: 22261707
[TBL] [Abstract][Full Text] [Related]
40. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
Landau MS; Kuan SF; Chiosea S; Pai RK
Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
